Physician profile
Robert R Bruce
NPI 1407877970
$1,732.71
in general payments reported to CMS, 2019-2025
31 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $196 · 2021: $286 · 2022: $236 · 2023: $363 · 2024: $135 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $217.43 | 2019-2025 | |
| Janssen Biotech, INC. | $182.95 | 2019-2022 | |
| Palette Life Sciences, INC. | $144.98 | 2023 | |
| Astellas Pharma US INC | $135.70 | 2019-2021 | |
| Boston Scientific Corporation | $100.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $100.16 | 2023-2025 | |
| Procept Biorobotics Corporation | $96.71 | 2023 | Aquabeam Robotic System |
| Seagen INC. | $96.28 | 2021 | |
| Bluewind Medical | $84.34 | 2024-2025 | Revi |
| Abbvie INC. | $61.44 | 2022-2024 | |
| Tolmar Pharmaceuticals, INC. | $59.99 | 2019-2020 | |
| Amgen INC. | $47.29 | 2020 | |
| Teleflex LLC | $39.69 | 2022-2023 | Urolift |
| Ferring Pharmaceuticals INC. | $36.17 | 2023 | Adstiladrin |
| Allergan, INC. | $35.90 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $32.60 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.54 | 2020-2022 | |
| Blue Earth Diagnostics | $30.74 | 2021-2022 | |
| Conmed Corporation | $28.22 | 2023 | Airseal |
| Urovant Sciences INC | $22.73 | 2021 | |
| Neotract INC. | $22.50 | 2020 | |
| Antares Pharma, INC. | $20.10 | 2019 | |
| Novo Nordisk INC | $18.47 | 2024 | Rivfloza |
| Sumitomo Pharma America, INC. | $17.07 | 2023 | Gemtesa |
| Clarus Therapeutics INC. | $15.10 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.08 | 2020 | |
| Zyla Life Sciences, INC. | $14.01 | 2019 | |
| Endo Pharmaceuticals INC. | $13.75 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.